Trinity Delta is highly optimistic about Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s recent phase II study results, predicting a 90% chance of success for the next phase of the evaluation.
The life sciences research house believes that the strong data effectively proves the concept of using Scancell's SCIB vaccine along with other cancer-fighting drugs. It also anticipates significant industry interest and sees potential for Scancell's vaccine to be used in broader applications.
Scancell recently reported that its study on SCIB1, a vaccine for advanced skin cancer, showed an 82% success rate in shrinking tumours.
This is a big deal because the study aimed for a 70% success rate and exceeded it. The vaccine seems to work well with other drugs, known as checkpoint inhibitors, to boost the body's natural defences against cancer.
According to Trinity Delta, the study's success is even more impressive when compared to other treatments.
Usually, the best results seen in this type of advanced skin cancer are around a 48-58% success rate.
Scancell's study is now moving to the next phase, where it plans to treat 27 more patients.
The company also plans to test an enhanced version of the vaccine, which could potentially work for all skin cancer patients and is more potent.
Trinity Delta expects data from these new tests by the first half of 2024. It also noted that Scancell is likely to explore partnerships and other business deals, given the strength of these results.
The research currently values Scancell at £300.1 million, or 36.7 pence per share.
The stock, up 20% in early trade, is currently changing hands for 15.82p.